Biotech Bullish Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Idera Pharmaceuticals (NASDAQ:IDRA), CytRx Corporation (NASDAQ:CYTR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

FB Nasdaq FB Facebook

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is 6.6% higher, as traders digest rumors that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was willing to pay over $20 per share to buy the firm. Digging deeper, speculators are expecting ARIA to remain south of $9 in the short term, buying to open the April 9 and May 9 puts. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 5.00% in last session and finished the day at $7.98. Traded volume was 20.70million shares in the last session and the average volume of the stock remained 20.74million shares. The beta of the stock remained 1.42. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.70%.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400. Idera Pharmaceuticals Inc (NASDAQ:IDRA) rose 17.78 percent to $4.57Friday on volume of 19.70million shares. The intra-day range of the stock was $4.22 to $4.80. Idera Pharmaceuticals Inc (NASDAQ:IDRA) has a market capitalization of $376.39million.

The Shareholders Foundation announces that an investor, who purchased shares of CytRx Corporation (NASDAQ:CYTR), filed a lawsuit in the U.S. District Court for the Central District of California over alleged violations of Federal Securities Laws by CytRx Corporation (NASDAQ:CYTR) in connection with certain allegedly false and misleading statements made between November 22, 2013 and March 13, 2014. CytRx Corporation (NASDAQ:CYTR)’s stock on Mar 28, 2014 reported a increase of 7.86% to the closing price of $3.43. Its fifty two weeks range is $1.95-$8.35. The total market capitalization recorded $190.59million. The overall volume in the last trading session was 2.20million shares. In its share capital, CYTR has 40.29million outstanding shares.

CORT has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. The stock has moved higher by 31.4% in the past month, while it is also above its 20 Day SMA too. On Friday, shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) advanced 5.44% to close the day at $4.07. Company return on investment (ROI) is -74.10% and its monthly performance is recorded as -1.21%. Corcept Therapeutics Incorporated (NASDAQ:CORT) quarterly revenue growth is 33.01%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone